Skip to main content
. 2020 Jun 14;2020:2806042. doi: 10.1155/2020/2806042

Figure 2.

Figure 2

Survival analysis of the expression level of RP11-838N2.3 in LAD. (a) Survival analysis shown that OS (overall survival) of high RP11-838N2.3 expression in the cisplatin-sensitive LAD group was lower (P < 0.001) than that of low RP11-838N2.3 expression in the cisplatin-sensitive LAD group. (b) Survival analysis showed that DFS (progression-free survival) of high RP11-838N2.3 expression in the cisplatin-sensitive LAD group was lower (P < 0.001) than that of low RP11-838N2.3 expression in the cisplatin-sensitive LAD group. (c) OS of high RP11-838N2.3 expression in the cisplatin-insensitive LAD group was lower (P < 0.001) than that of low RP11-838N2.3 expression in the cisplatin-insensitive LAD group. (d) DFS of high RP11-838N2.3 expression in the cisplatin-insensitive LAD group was lower (P < 0.001) than that of low RP11-838N2.3 expression in the cisplatin-insensitive LAD group.